A Study of THR-184 in Patients at Risk of Developing Cardiac Surgery Associated-Acute Kidney Injury (CSA-AKI)

PHASE2CompletedINTERVENTIONAL
Enrollment

452

Participants

Timeline

Start Date

May 31, 2013

Primary Completion Date

September 30, 2015

Study Completion Date

September 30, 2015

Conditions
Acute Kidney Injury
Interventions
DRUG

THR-184

THR-184 is a synthetic oligopeptide administered intravenously.

DRUG

Placebo

A normal saline solution identical in appearance to the active drug solution

Trial Locations (41)

10032

Columbia University, New York

12208

St. Peter's Hospital, Albany

20814

Suburban Hospital, Bethesda

21287

John Hopkins University, Baltimore

23225

Cardiothoracic Surgical Associates, Richmond

27710

Duke University Medical Center, Durham

Durham VA Medical Center, Durham

32207

River City Clinical Research, Jacksonville

35294

University of Alabama-Birmingham, Birmingham

37212

Vanderbilt University Medical Center, Nashville

37404

Erlanger Health System, Chattanooga

Memorial Hospital, Chattanooga

43210

The Ohio State University Medical Center, Columbus

45219

Lindner Research Center-Christ Hospital, Cincinnati

46290

Indiana Heart-St. Vincent Medical Group, Indianapolis

46804

Indiana Ohio Heart, Fort Wayne

48602

Covenant Medical Center, Saginaw

49770

Cardiac and Vascular Research Center of Northern Michigan, Petoskey

60453

Advocate Christ Medical Center, Oak Lawn

60637

University of Chicago, Chicago

63110

Washington University, St Louis

75226

Baylor University Medical Center, Soltero Cardiovascular Research Center, Dallas

77030

University of Texas, Houston, Houston

90033

University of Southern California, Los Angeles

90503

Harbor - University of California Los Angeles Medical Center, Torrance

94305

Stanford University, Stanford

06810

Danbury Hospital, Danbury

04102

Maine Medical Center, Portland

02114

Massachusetts General Hospital, Boston

01199

Baystate Medical Center, Springfield

07503

St. Joseph's Regional Medical Center, Paterson

T2N 2T9

Foothills Medical Centre, Calgary

E2L4L2

St-John Regional Hospital Facility, Saint John

L8L 2X2

Hamilton Health Sciences Corporation, Hamilton

K1Y 4W7

University of Ottawa Heart Institute, Ottawa

M5B 1W8

St. Michael's Hospital, Toronto

H1T 1C8

Institut de Cardiologie de Montréal, Montreal

H2W 1T8

Centre hospitalier de l'université de Montréal(CHUM)- Hôtel-Dieu, Montreal

H3A 1A1

MUHC - Royal Victoria Hospital, Montreal

H4J 1C5

Sacre Cœur Hospital, Montreal

G1V 4G5

Institut Universitaire de Cardiologie et de Pneumologie de Québec, Québec

All Listed Sponsors
lead

Thrasos Innovation, Inc.

INDUSTRY

NCT01830920 - A Study of THR-184 in Patients at Risk of Developing Cardiac Surgery Associated-Acute Kidney Injury (CSA-AKI) | Biotech Hunter | Biotech Hunter